Hoff Paulo M, Pazdur Richard
Department of Gastrointestinal Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Oncology (Williston Park). 2004 May;18(6):705-8.
Colorectal cancer remains one of the major causes of cancer death worldwide, but the past few years have witnessed the development of a number of new, effective treatment options, which have led to considerable improvement in the survival rate for patients suffering from this common cancer. The advent of agents such as capecitabine (Xeloda), irinotecan (Camptosar), and oxaliplatin (Eloxatin), and newer molecular targeted agents such as cetuximab (Erbitux) and bevacizumab (Avastin) brought innovation to the treatment of colorectal cancer. Oncologists are no longer restricted to using fluorouracil and its variations as the only active treatment, and the number of patients who are able to live longer continues to increase. Patients presenting with stage III cancer can expect a greater chance for cure, and those presenting with metastatic disease can expect a median survival approaching 2 years.
结直肠癌仍然是全球癌症死亡的主要原因之一，但在过去几年中出现了许多新的有效治疗方案，这使得这种常见癌症患者的生存率有了显著提高。卡培他滨（希罗达）、伊立替康（开普拓）和奥沙利铂（乐沙定）等药物，以及西妥昔单抗（爱必妥）和贝伐单抗（安维汀）等更新的分子靶向药物的出现，为结直肠癌的治疗带来了创新。肿瘤学家不再局限于将氟尿嘧啶及其变体作为唯一的有效治疗方法，能够延长生存期的患者数量持续增加。患有III期癌症的患者有望获得更大的治愈机会，而患有转移性疾病的患者预计中位生存期接近2年。
